Synergistic drug combinations and machine learning for drug repurposing in chordoma.

ABSTRACT: Chordoma is a devastating rare cancer that affects one in a million people. With a mean-survival of just 6 years and no approved medicines, the primary treatments are surgery and radiation. In order to speed new medicines to chordoma patients, a drug repurposing strategy represents an attractive approach. Drugs that have already advanced through human clinical safety trials have the potential to be approved more quickly than de novo discovered medicines on new targets. We have taken two strategies to enable this: (1) generated and validated machine learning models of chordoma inhibition and screened compounds of interest in vitro. (2) Tested combinations of approved kinase inhibitors already being individually evaluated for chordoma. Several published studies of compounds screened against

SUBMITTER: Anderson E 

PROVIDER: S-EPMC7395084 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature